EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fetal Hemoglobin Decrease During Voxelotor Treatment

Gonzalo De Luna iD, Anoosha Habibi, Stéphane Moutereau, Suella Martino, Jamila Alhamrouni, Celia Morel, Yanis Pelinski iD, Yosr Zaouali, Frédéric Galactéros, Pablo Bartolucci

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Gonzalo De Luna und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, Créteil, France. Hauptthemen laut MEDLINE: Fetal Hemoglobin, Anemia, Sickle Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voxelotor modifies hemoglobin‐oxygen affinity improving anemia and reducing hemolysis in sickle cell patients. However, the impact of Voxelotor on fetal hemoglobin (HbF) levels is unknown. We describe here variations of percentage of HbF measured by high performance liquid chromatography and mean corpuscular fetal Hb in a cohort of sickle cell patients treated with Voxelotor at Henri Mondor Sickle Cell Referral Center. Our data show a decrease in HbF levels in sickle cell patients after 6 months of treatment with Voxelotor, which is likely to be associated with an increase in the lifespan of red blood cells that are no longer prematurely removed from the circulation, particularly those with low HbF. This work raises the question of the risk of a rebound effect when stopping Voxelotor, which has a short half‐life, during the time it takes to increase HbF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fetal HemoglobinAnemia, Sickle CellHumansMaleFemaleAdultPyrazinesAdolescentErythrocyte IndicesYoung AdultAntisickling AgentsTreatment OutcomeMiddle AgedBenzaldehydesPyrazoles

Stichwörter der Autor:innen

Voxelotorfetal hemoglobinhematopoiesissickle cell disease

Substanzen

Fetal HemoglobinvoxelotorPyrazinesAntisickling AgentsBenzaldehydesPyrazoles

Autor:innen und Institutionen

  • Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, Créteil, France.
  • Département de Biochimie-Biologie Moléculaire-Pharmacologie-Génétique Médicale, Henri-Mondor University Hospital- UPEC, Créteil, France.
  • Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance, Henri-Mondor University Hospital- UPEC, Créteil, France.
  • Université Paris-Est Créteil, INSERM, IMRB, Laboratory of Excellence LABEX GRex, Créteil, France.

ORCID-Profile: Gonzalo De Luna, Yanis Pelinski

Zitieren

APA

De Luna, G., Habibi, A., Moutereau, S., Martino, S., Alhamrouni, J., Morel, C., Pelinski, Y., Zaouali, Y., Galactéros, F., & Bartolucci, P. (2025). Fetal Hemoglobin Decrease During Voxelotor Treatment. European Journal of Haematology. https://doi.org/10.1111/ejh.14332

Vancouver

De Luna G, Habibi A, Moutereau S, Martino S, Alhamrouni J, Morel C, et al. Fetal Hemoglobin Decrease During Voxelotor Treatment. European Journal of Haematology. 2025. doi:10.1111/ejh.14332

BibTeX
@article{DeLuna2025,
  author = {De Luna, Gonzalo and Habibi, Anoosha and Moutereau, Stéphane and Martino, Suella and Alhamrouni, Jamila and Morel, Celia and Pelinski, Yanis and Zaouali, Yosr and Galactéros, Frédéric and Bartolucci, Pablo},
  title = {Fetal Hemoglobin Decrease During Voxelotor Treatment},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14332}
}
Kostenlos starten →